Saturday 23 November 2024

The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?

Biotechnology
Simon Wentworth
14 December 2021
kirill_dmitriev_rdif_podcast

More on this story...

Biotechnology
RDIF and AstraZeneca invest in aldosterone synthase inhibitor for arterial hypertension
1 February 2022
Pharmaceutical
Russia's Sputnik Light coronavirus vaccine approved in India
7 February 2022
Pharmaceutical
RDIF and Serum Institute agree manufacturing deal for Sputnik V
13 July 2021
Pharmaceutical
RDIF and UNICEF sign Sputnik V vaccine supply deal
27 May 2021


Companies featured in this story

More ones to watch >


Today's issue

Takeda launches Fruzaqla in Japan
Biotechnology
Takeda launches Fruzaqla in Japan
22 November 2024
Biotechnology
CStone out-licenses sugemalimab rights in MENA region
22 November 2024
Biotechnology
China's regulator to review Akeso's checkpoint blocker
22 November 2024
Biotechnology
Paragon Therapeutics appoints first chief executive
22 November 2024
Pharmaceutical
Pfizer to help commercialize Xacduro in China
22 November 2024
Pharmaceutical
Amid RFK Jr vaccine worries, FDA’s Peter Marks remains calm
22 November 2024
Biotechnology
Versant Ventures unveils obesity focused Pep2Tango Therapeutics
22 November 2024

Company Spotlight

A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.




More Features in Biotechnology

Takeda launches Fruzaqla in Japan
22 November 2024
CStone out-licenses sugemalimab rights in MENA region
22 November 2024
China's regulator to review Akeso's checkpoint blocker
22 November 2024
Paragon Therapeutics appoints first chief executive
22 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze